Over the last decade, there has been a fervent interest in less invasive approaches to valvular and structural interventions, with the goal of decreasing procedural risk, improving clinical outcomes, and extending therapy to high and prohibitive-risk populations. This has been realized with the development of transcatheter valve interventions for patients with aortic, tricuspid or mitral valve disease, amongst other advancements.
TAVI has created a huge momentum in heart valve innovations and has set the stage for future transcatheter valve technologies that are tackling the other three valves of the heart through less-invasive procedures.
1- To improve the outcome of patients after TAVI
How to encourage the approach of minimalist TAVI and reduce the rate of conduction abnormalities and pacemaker implantation after TAVI? New concepts and research papers.
2- To improve the outcome of patients with mitral and tricuspid valve disease undergoing TEER and direct annuloplasty.
What is the role of the new innovative transcatheter valve replacement technologies in treatment of patients with mitral and tricuspid valve disease?
3- To underscore the role of inflammatory markers and other epigenetic markers in valvular heart diseases and their impact of the remodellung after trnscatheter interventions.
4- To examine novel markers as emerging surrogates of inflammation and fibro-calcific remodelling (e.g. assessed by PET/CT with 18F-NaF/18F-FDG) which can provide incremental information on top of echocardiography, and likely represent more accurate measures of disease activity.
We are willing to coordinate and present original research and meta-analytic studies, review articles, case reports and editorials regarding these innovative techniques in the field of valvular and structural heart disease.
Over the last decade, there has been a fervent interest in less invasive approaches to valvular and structural interventions, with the goal of decreasing procedural risk, improving clinical outcomes, and extending therapy to high and prohibitive-risk populations. This has been realized with the development of transcatheter valve interventions for patients with aortic, tricuspid or mitral valve disease, amongst other advancements.
TAVI has created a huge momentum in heart valve innovations and has set the stage for future transcatheter valve technologies that are tackling the other three valves of the heart through less-invasive procedures.
1- To improve the outcome of patients after TAVI
How to encourage the approach of minimalist TAVI and reduce the rate of conduction abnormalities and pacemaker implantation after TAVI? New concepts and research papers.
2- To improve the outcome of patients with mitral and tricuspid valve disease undergoing TEER and direct annuloplasty.
What is the role of the new innovative transcatheter valve replacement technologies in treatment of patients with mitral and tricuspid valve disease?
3- To underscore the role of inflammatory markers and other epigenetic markers in valvular heart diseases and their impact of the remodellung after trnscatheter interventions.
4- To examine novel markers as emerging surrogates of inflammation and fibro-calcific remodelling (e.g. assessed by PET/CT with 18F-NaF/18F-FDG) which can provide incremental information on top of echocardiography, and likely represent more accurate measures of disease activity.
We are willing to coordinate and present original research and meta-analytic studies, review articles, case reports and editorials regarding these innovative techniques in the field of valvular and structural heart disease.
